Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Lymphoid 1Genitourinary 1Breast 1

Conditions

Rectal Neoplasms 2Prostatic Neoplasms 1Neoplasms 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 324Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Rifaximin × Gastrointestinal × Clear all
NCT06783153 2025-01-20

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

Mansoura University

Phase 1/2 Not yet recruiting
80 enrolled
GastrointestinalGenitourinary

Neoplasms, Prostatic Neoplasms, Rectal Neoplasms

NCT01345175 2024-05-14

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

Memorial Sloan Kettering Cancer Center

Phase 3 Completed
69 enrolled 9 charts
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡